Search results
Showing 6991 to 7005 of 8224 results
This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).
This quality standard has been updated and replaced by NICE quality standard 184.
This quality standard has been updated and replaced by NICE quality standard 212.
This quality standard has been updated and replaced by NICE quality standard 211.
This quality standard has been updated and replaced by NICE quality standard 180.
This quality standard has been updated and replaced by NICE quality standard 211.
Venous thromboembolism in adults: diagnosis and management (QS29)
This quality standard has been updated and replaced by NICE quality standard QS201.
Venous thromboembolism in adults: reducing the risk in hospital (QS3)
This quality standard has been updated and replaced by NICE quality standard QS201.
This quality standard has been updated and replaced by NICE quality standard 184.
This quality standard has been withdrawn. Specialist neonatal care is covered in the NICE quality standards for specialist neonatal respiratory care for babies born pre-term, developmental follow-up of children and young people born preterm, maternal and child nutrition and postnatal care.
This quality standard has been updated and replaced by NICE quality standard 207.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
May 2022: This guidance has been withdrawn. For the latest guidance, see the UK Kidney Association’s recommendations for minimising the risk of transmission of COVID-19 in adult haemodialysis units. See also NICE's guideline on managing COVID-19.
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.